Work

Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.3_suppl.127

Authors: Daneng Li, Hee Kyung Kim, Sun Young Kim, Sunil Sharma, Sang Joon Shin, Jeeyun Lee, Byoung Yong Shim, Keon Uk Park, Sung Yong Oh, Seock-Ah Im, Yun-Gyoo Lee, Kristine Xiaohong She, Wenda Li, Ping Xiao, Guizhong Liu, Songmao Zheng, Michael Jon Chisamore, Peter Luo, Jiping Zha, Manish R. Patel

Institutions: City of Hope, Chungbuk National University, Chungbuk National University Hospital, Asan Medical Center, University of Ulsan, HonorHealth, Yonsei University, Severance Hospital, Samsung Medical Center, The Catholic University of Korea St. Vincent's Hospital, Keimyung University Dongsan Hospital, Keimyung University, Dong-A University Hospital, Seoul National University, Seoul National University Hospital, Kangbuk Samsung Hospital, Sungkyunkwan University, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391090924

Cites:

Cited by: 1

Related to: 10